These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9520908)

  • 81. DHEA-S plasma levels and incidence of Alzheimer's disease.
    Hillen T; Lun A; Reischies FM; Borchelt M; Steinhagen-Thiessen E; Schaub RT
    Biol Psychiatry; 2000 Jan; 47(2):161-3. PubMed ID: 10664834
    [TBL] [Abstract][Full Text] [Related]  

  • 82. DHEA treatment of Alzheimer's disease: A randomized, double-blind, placebo-controlled trial.
    Leblhuber F; Haller H; Steiner K; Fuchs D
    Neurology; 2004 Mar; 62(6):1030. PubMed ID: 15037728
    [No Abstract]   [Full Text] [Related]  

  • 83. Oxidative Stress-Mediated Brain Dehydroepiandrosterone (DHEA) Formation in Alzheimer's Disease Diagnosis.
    Rammouz G; Lecanu L; Papadopoulos V
    Front Endocrinol (Lausanne); 2011; 2():69. PubMed ID: 22654823
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Dehydroepiandrosterone sulphate in Alzheimer disease.
    Späth-Schwalbe E; Dodt C; Dittmann J; Schüttler R; Fehm HL
    Lancet; 1990 Jun; 335(8702):1412. PubMed ID: 1971699
    [No Abstract]   [Full Text] [Related]  

  • 85. 7 alpha-hydroxy-dehydroepiandrosterone and immune response.
    Morfin R; Lafaye P; Cotillon AC; Nato F; Chmielewski V; Pompon D
    Ann N Y Acad Sci; 2000; 917():971-82. PubMed ID: 11268429
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Identification and quantification of dehydroepiandrosterone sulphate in saliva.
    Finlay EM; Morton MS; Gaskell SJ
    Steroids; 1982 Jan; 39(1):63-71. PubMed ID: 6210977
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reduced sulfotransferase SULT2A1 activity in patients with Alzheimer's disease.
    Vaňková M; Hill M; Velíková M; Včelák J; Vacínová G; Lukášová P; Vejražková D; Dvořáková K; Rusina R; Holmerová I; Jarolímová E; Vaňková H; Bendlová B
    Physiol Res; 2015; 64(Suppl 2):S265-73. PubMed ID: 26680489
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease.
    Sunderland T; Merril CR; Harrington MG; Lawlor BA; Molchan SE; Martinez R; Murphy DL
    Lancet; 1989 Sep; 2(8662):570. PubMed ID: 2570275
    [No Abstract]   [Full Text] [Related]  

  • 89. Identification of 16alpha,19-dihydroxyandrostenedione in the serum of pregnant women by gas chromatography-mass spectrometry.
    Numazawa M; Satoh S; Nagaoka M; Honjo H; Osawa Y
    Biol Pharm Bull; 2001 Aug; 24(8):947-9. PubMed ID: 11510491
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Dehydroepiandrosterone modulates oxidative DNA damage in pancreatic cancer: A case-control study.
    Fazli HR; Mohamadkhani A; Godarzi HR; Pourshams A; Jafari Nia M
    JGH Open; 2021 Aug; 5(8):902-906. PubMed ID: 34386598
    [TBL] [Abstract][Full Text] [Related]  

  • 91. DHEA for Alzheimer's disease: a modest showing by a superhormone.
    Knopman D; Henderson VW
    Neurology; 2003 Apr; 60(7):1060-1. PubMed ID: 12682305
    [No Abstract]   [Full Text] [Related]  

  • 92. The relationship of plasma 7 alpha-hydroxy dehydroepiandrosterone to disease stage and adrenal androgens in breast cancer patients.
    Skinner SJ; Couch RA; Thambyah S; Dobbs RJ; Jordan SM; Mason B; Kay RG
    Eur J Cancer (1965); 1980 Feb; 16(2):223-8. PubMed ID: 6445272
    [No Abstract]   [Full Text] [Related]  

  • 93. Studies on the synthesis of dehydroepiandrosterone (DHEA) phosphatide.
    Williams JR; Boehm JC
    Steroids; 1995 Apr; 60(4):333-6. PubMed ID: 8539787
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The effect of dehydroepiandrosterone sulfate administration on the 16alpha-hydroxy-dehydroepiandrosterone excretion in cirrhotic patients.
    Ruiz Gonzalez MC; Martinez Venano J; Oriol-Bosch A
    J Steroid Biochem; 1976 Oct; 7(10):862-6. PubMed ID: 138027
    [No Abstract]   [Full Text] [Related]  

  • 95. Antiglucocorticoid actions of dehydroepiandrosterone and low concentrations in Alzheimer's disease.
    Svec F; Lopez A
    Lancet; 1989 Dec; 2(8675):1335-6. PubMed ID: 2574281
    [No Abstract]   [Full Text] [Related]  

  • 96. A Review on MS-Based Blood Biomarkers for Alzheimer's Disease.
    Oeckl P; Otto M
    Neurol Ther; 2019 Dec; 8(Suppl 2):113-127. PubMed ID: 31833028
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Pan X; Wu X; Kaminga AC; Wen SW; Liu A
    Front Aging Neurosci; 2019; 11():61. PubMed ID: 30983988
    [No Abstract]   [Full Text] [Related]  

  • 98. Comparative modeling of 25-hydroxycholesterol-7α-hydroxylase (CYP7B1): ligand binding and analysis of hereditary spastic paraplegia type 5 CYP7B1 mutations.
    Siam A; Brancale A; Simons C
    J Mol Model; 2012 Feb; 18(2):441-53. PubMed ID: 21541746
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS).
    Maninger N; Wolkowitz OM; Reus VI; Epel ES; Mellon SH
    Front Neuroendocrinol; 2009 Jan; 30(1):65-91. PubMed ID: 19063914
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Increased total 7 alpha-hydroxy-dehydroepiandrosterone in serum of patients with Alzheimer's disease.
    Attal-Khémis S; Dalmeyda V; Michot JL; Roudier M; Morfin R
    J Gerontol A Biol Sci Med Sci; 1998 Mar; 53(2):B125-32. PubMed ID: 9520908
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.